Open AccessSingle tertiary cancer center experience on the management of pT3b prostate cancer after robotic-assisted laparoscopic prostatectomy
Author(s) -
Arvind Nayak,
Omar ElTaji,
Sugeeta Sukumar,
John Piedad,
Aruni Ghose,
Robert C Hughes,
R. Alonzi,
Peter Ostler,
Anand Sharma,
Tim Lane,
Jim Adshead,
Nikhil Vasdev
Publication year - 2022
Publication title -
current urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.476
H-Index - 13
eISSN - 1661-7657
pISSN - 1661-7649
DOI - 10.1097/cu9.0000000000000115
Subject(s) - medicine , prostatectomy , prostate cancer , radiation therapy , laparoscopic radical prostatectomy , androgen deprivation therapy , cancer , urology , surgery
Pathological involvement of the seminal vesicle poses a treatment dilemma following robotic prostatectomy. Margin status plays an important role in deciding further management. A wide range of treatment options are available, including active monitoring, adjuvant radiotherapy, salvage radiotherapy, and occasionally androgen deprivation therapy. Patients undergoing postoperative radiotherapy tend to have higher risk of urinary and bowel morbidities. The recent RADICALS-RT concluded that adjuvant radiotherapy did not have any benefit compared with salvage radiotherapy. We aim to audit the incidence, margin status, and management of T3b cancer cases at our center.